Skip to main content

vs-7375

Generic: KRAS G12D Inhibitor VS-7375·Code: VS-7375, GFH375

vs-7375: sourced relationships with 1 company · 4 clinical trials tracked.

vs-7375 evidence translation

What we can confirm

4 tracked trials

What it means

Source-backed records connect vs-7375 to VSTM; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

How could vs-7375 → VSTM affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence5 indications · 0 study sponsors

Related indications

Non-Small Cell Lung Cancer; Pancreatic Ductal Adenocarcinoma (PDAC); Pancreatic Ductal AdenocarcinomaColorectal CancerNon-Small Cell Lung CancerPancreatic Ductal AdenocarcinomaPancreatic Ductal Adenocarcinoma (PDAC)

Study sponsors

No additional listed-company sponsor is linked.

Dated Pipeline Records (1)
CompanyDated record stage
Verastem, Inc. (VSTM)
licensee · Reported 2025-03-20 · Current development: unknownSource
Non-Small Cell Lung Cancer; Pancreatic Ductal Adenocarcinoma…
Phase 2
Clinical Trial Registry Records (4)

A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, With and Without an Anti-EGFR Antibody, and With an Anti-EGFR Antibody and Chemotherapy, in Patients With Metastatic KRAS G12D-Mutated Colorectal Adenocarcinoma (TARGET-D 203)

NCT07659795Registry updated 2026-10-06·Phase 2·VSTM
Recruiting

Primary endpoint: Confirmed ORR by blinded independent central review (BICR) per RESIST v1.1 - 2L CRC only

InterventionalRandomizedsingle150 targetStarted 2026-07Completion 2028-1222 sites · Australia, United StatesVerastem, Inc.

A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients With Previously Treated, Advanced KRAS G12D-Mutated Non-Small Cell Lung Cancer (TARGET-D 202)

NCT07659782Registry updated 2026-10-07·Phase 2·VSTM
Recruiting

Primary endpoint: Confirmed ORR by blinded independent central review (BICR) per RESIST v1.1

InterventionalRandomizedsingle105 targetStarted 2026-07Completion 2028-1219 sites · Australia, Puerto Rico, United StatesVerastem, Inc.

A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and With Cetuximab, in Patients With Metastatic KRAS G12D-Mutated Pancreatic Cancer (TARGET-D 201)

NCT07644559Registry updated 2026-09-03·Phase 2·VSTM
Recruiting

Primary endpoint: Confirmed ORR by blinded independent central review (BICR) per RESIST v1.1

InterventionalRandomizedsingle180 targetStarted 2026-06Completion 2028-1229 sites · Australia, Canada, United StatesVerastem, Inc.

A Phase 1/2, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients With Advanced KRAS G12D-Mutated Solid Tumors

NCT07020221Registry updated 2026-04-22·Phase 1/Phase 2·VSTM
Recruiting

Primary endpoint: Part A: To characterize the safety, tolerability, and AE profile of escalating doses of VS-7375

Interventionalopen295 targetStarted 2025-06Completion 2028-1214 sites · Australia, United StatesVerastem, Inc.

Frequently asked questions

Which companies have sourced relationships with vs-7375?

vs-7375 has dated SEC/FDA relationship records for Verastem, Inc..

How many clinical trials involve vs-7375?

BioSniper tracks 4 clinical trials involving vs-7375.